Genome-Scale Metabolic Models and Systems Medicine of Metabolic SyndromeNatal van Riel
workshop on 'The interplay of fat and carbohydrate metabolism with application in Metabolic Syndrome and Type 2 Diabetes', December 12 and 13, 2013, Eindhoven University of Technology
Genome-Scale Metabolic Models and Systems Medicine of Metabolic SyndromeNatal van Riel
workshop on 'The interplay of fat and carbohydrate metabolism with application in Metabolic Syndrome and Type 2 Diabetes', December 12 and 13, 2013, Eindhoven University of Technology
Roche Quantitative Systems Pharmacology methodology workshop
February 4th-5th, 2016, Basel, Switzerland
Bringing multi-level systems pharmacology models to life
Natal van Riel
Abstract
Computational modelling in Systems Medicine and Systems Pharmacology addresses biological processes at different levels and scales. The quantification of model parameters from experimental data is a complicated task. It will be addressed how variance in data propagates into parameter estimates and, more importantly, model predictions. The Analysis of Dynamic Adaptations in Parameter Trajectories (ADAPT) approach is discussed as method to model dynamics at multiple time-scales. Two examples will be provided: 1) modelling of longitudinal data in a cohort of Type 2 Diabetics using different medication, and 2) the application in preclinical research studying the effect of liver X receptor activation on HDL metabolism and liver steatosis.
MouseAGE Kickoff conference
Braga, Portugal
23 Mar 2015 to 25 Mar 2015
COST Action MouseAGE: Preclinical testing of interventions in mouse models of age and age-related diseases
http://www.cost.eu/COST_Actions/bmbs/Actions/BM1402
Disseminating the FP7 Systems Medicine of Metabolic Syndrome project RESOLVE (http://www.resolve-diabetes.org)
Quantification of variability and uncertainty in systems medicine modelsNatal van Riel
BioSB2016 Conference
Abstract: Computational modelling in systems biology addresses biological processes at different levels and scales. The quantification of model parameters from experimental data is a complicated task. To develop accurate, predictive models it is necessary to analyze how variance in data propagates into parameter estimates and, more importantly, model predictions. The network structure of the biological systems imposes strong constraints on possible solutions of a model. Amounts of data, available at molecular and physiological level, continue to increase. Often, model results are only partly in agreement with data, despite that model parameters are fitted. In contrast to existing belief that calibration of systems biology models to experimental data is prone to overfitting, we argue that dynamical models, despite their size and complexity, are not flexible enough to correctly describe all data.
Approaches are explored to introduce more degrees of freedom in models, but simultaneously enforcing sparsity if extra flexibility is not required. Estimation tools for dynamical systems are complemented with ‘regularization’ methods to reduce the error (bias) in models without escalating uncertainties (variance). This paradigm shift will be illustrated in two examples: 1) modelling of longitudinal data in a cohort of Type 2 Diabetics using different medication, and 2) the application in preclinical research studying the effect of liver X receptor activation on HDL metabolism and liver steatosis.
Roche Quantitative Systems Pharmacology methodology workshop
February 4th-5th, 2016, Basel, Switzerland
Bringing multi-level systems pharmacology models to life
Natal van Riel
Abstract
Computational modelling in Systems Medicine and Systems Pharmacology addresses biological processes at different levels and scales. The quantification of model parameters from experimental data is a complicated task. It will be addressed how variance in data propagates into parameter estimates and, more importantly, model predictions. The Analysis of Dynamic Adaptations in Parameter Trajectories (ADAPT) approach is discussed as method to model dynamics at multiple time-scales. Two examples will be provided: 1) modelling of longitudinal data in a cohort of Type 2 Diabetics using different medication, and 2) the application in preclinical research studying the effect of liver X receptor activation on HDL metabolism and liver steatosis.
MouseAGE Kickoff conference
Braga, Portugal
23 Mar 2015 to 25 Mar 2015
COST Action MouseAGE: Preclinical testing of interventions in mouse models of age and age-related diseases
http://www.cost.eu/COST_Actions/bmbs/Actions/BM1402
Disseminating the FP7 Systems Medicine of Metabolic Syndrome project RESOLVE (http://www.resolve-diabetes.org)
Quantification of variability and uncertainty in systems medicine modelsNatal van Riel
BioSB2016 Conference
Abstract: Computational modelling in systems biology addresses biological processes at different levels and scales. The quantification of model parameters from experimental data is a complicated task. To develop accurate, predictive models it is necessary to analyze how variance in data propagates into parameter estimates and, more importantly, model predictions. The network structure of the biological systems imposes strong constraints on possible solutions of a model. Amounts of data, available at molecular and physiological level, continue to increase. Often, model results are only partly in agreement with data, despite that model parameters are fitted. In contrast to existing belief that calibration of systems biology models to experimental data is prone to overfitting, we argue that dynamical models, despite their size and complexity, are not flexible enough to correctly describe all data.
Approaches are explored to introduce more degrees of freedom in models, but simultaneously enforcing sparsity if extra flexibility is not required. Estimation tools for dynamical systems are complemented with ‘regularization’ methods to reduce the error (bias) in models without escalating uncertainties (variance). This paradigm shift will be illustrated in two examples: 1) modelling of longitudinal data in a cohort of Type 2 Diabetics using different medication, and 2) the application in preclinical research studying the effect of liver X receptor activation on HDL metabolism and liver steatosis.